High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes.
Hovens
M M C
MM
Snoep
J D
JD
Groeneveld
Y
Y
Tamsma
J T
JT
Eikenboom
J C J
JC
Huisman
M V
MV
D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D008078:Cholesterol, LDL; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D001241:Aspirin